NCT02153645View on ClinicalTrials.gov

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

PHASE3TerminatedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

August 18, 2014

Primary Completion Date

May 20, 2016

Study Completion Date

May 20, 2016

Conditions
Parkinson's DiseaseLevodopa Induced Dyskinesias (LID)
Interventions
DRUG

240mg Amantadine HCl ER tablets

DRUG

Placebo tablets

DRUG

320mg Amantadine HCl ER tablets

Trial Locations (56)

11020

Manhasset

11203

Brooklyn

11772

Patchogue

13088

Berlin

13385

Marseille

27612

Raleigh

31008

Pamplona

33021

Hollywood

33101

Miami

33403

North Palm Beach

33612

Tampa

43221

Columbus

46202

Indianapolis

48103

Ann Arbor

48109

Ann Arbor

60612

Chicago

69677

Bron

70810

Baton Rouge

78681

Round Rock

80304

Boulder

84058

Orem

85724

Tucson

91105

Pasadena

91335

Reseda

92697

Irvine

92708

Fountain Valley

93001

Ventura

93003

Ventura

97080

Würzburg

98034

Kirkland

07901

Summit

Unknown

London

Ottawa

Rennes

Amiens

Clermont-Ferrand

Créteil

Lille

Montauban

Nîmes

Paris

Poitiers

Toulouse

Haag

Erbach im Odenwald

Achim

Bochum

Weissensee

Berlin

Manresa

Seville

Alcorcón

Castellana

Barcelona

08036

Barcelona

08041

Barcelona

Sponsors
All Listed Sponsors
lead

Adamas Pharmaceuticals, Inc.

INDUSTRY

NCT02153645 - Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. | Biotech Hunter | Biotech Hunter